« Return to News | Awards & Advancement

VentiRx Pharmaceuticals appoints James Kyle Bryan as CMO

Thursday, April 25, 2013 08:00 AM

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases, has appointed James Kyle Bryan, M.D., as chief medical officer. 

A hematologist and medical oncologist, Bryan brings more than 20 years of oncology drug discovery and development experience in the pharmaceutical and biotechnology industry to VentiRx. This includes extensive operational and strategic leadership work in his previous roles as vice president of global product development at PPD, a global CRO, and as vice president of medical affairs at Seattle Genetics.

"Kyle will be integral in directing our clinical development efforts, which will  include our ongoing randomized, placebo-controlled phase II trial of VTX-2337 in combination with pegylated liposomal doxorubicin in patients with recurrent or persistent ovarian cancer and our upcoming phase II trial of VTX-2337 in head and neck cancer patients," said Robert Hershberg, M.D., Ph.D., CEO of VentiRx. "His extensive experience in oncology drug development combined with his strong connections to oncology thought leaders will be invaluable to VentiRx going forward.  We are delighted to have him join the VentiRx team."

Board-certified in medical oncology, hematology and internal medicine, Bryan currently serves on the clinical faculty of medicine for hematology and oncology at the University of Washington Medical Center. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.